DUBLIN, Ireland and TREVOSE, Pa. – Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it submitted a New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the treatment of endogenous Cushing’s syndrome to...
treatment News
DUBLIN, Ireland and TREVOSE, Pa. – Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application...
New York, NY – Structural insights into a potent antimalarial drug candidate’s interaction with the malaria parasite Plasmodium falciparum have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute. The antimalarial molecule, TDI-8304, is one of a new class...
Ridgefield, Conn. – Boehringer Ingelheim today announced results from an analysis of the SENSCIS®-ON trial. SENSCIS-ON is an open-label extension trial of the Phase III SENSCIS® study to assess the long-term tolerability and safety of Ofev® (nintedanib) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The study also evaluated...
Cincinnati, Ohio – An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson’s disease medication delivered through an infusion pump is safe and effective at reducing symptoms for longer periods of time. These results, published March 15 in the Lancet Neurology journal, could lead to...
ATLANTA – New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, found that JAK inhibitors (JAKi) and tocilizumab elicited better response rates in VEXAS syndrome compared to other targeted therapies. VEXAS syndrome is a rare and often fatal autoimmune condition caused by a mutation in...
ATLANTA — New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, found that rheumatoid arthritis (RA) patients in sustained remission who stopped TNF inhibitors (TNFi) had significantly more flares and lower Boolean 2.0 remission rates compared with those who continued treatment. Boolean 2.0 is a...
Wilmington, DE – Laser epilation, commonly known as laser hair removal, reduced the risk of recurrence in patients with pilonidal disease, an inflammatory, painful, and sometimes chronic or recurring condition, according to research conducted by Peter C. Minneci, M.D., Chair of Surgery at Nemours Children’s Health, Delaware Valley, and published...
Boston, Mass. – Programmed cell death 1 (PD-1) is an important target for immune checkpoint inhibitor therapies that block its signaling and boost T-cell activity. PD-1 inhibitors have been approved for treating various types of cancer. But PD-1 functions can vary between different cell and cancer types, either promoting or...
BOSTON–A stem cell transplant (SCT) from a compatible donor early in the course of disease is the best approach for the majority of young and middle-aged adult patients with acute myeloid leukemia (AML), according to a new analysis of two dozen clinical studies. The findings of the study, published in...